Financials Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Delayed OTC Markets 14:41:27 21/10/2026 BST			5-day change	1st Jan Change
15.76 ^USD	+1.81%		+7.57%	+16.48%

10-08	Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer	MT
10-08	Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer	CI

Projected Income Statement: Astellas Pharma Inc.

Projected Income Statement - Annual - Astellas Pharma Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Net sales ¹	1,296,163	1,518,619	1,603,672	1,912,323	2,139,245	2,371,429	2,209,470	1,970,501
Change	-	17.16%	5.6%	19.25%	11.87%	10.85%	-6.83%	-10.82%
EBITDA ¹	235,370	238,767	183,358	240,171	577,227	759,330	707,826	602,722
Change	-	1.44%	-23.21%	30.98%	140.34%	31.55%	-6.78%	-14.85%
EBIT ¹	155,686	133,029	25,518	41,039	382,633	508,953	476,158	370,335
Change	-	-14.55%	-80.82%	60.82%	832.36%	33.01%	-6.44%	-22.22%
Interest Paid ¹	-4,949	-8,779	-12,005	-17,677	-6,046	-10,293	-4,622	-5,900
Earnings before Tax (EBT) ¹	156,886	132,361	24,969	31,237	376,587	484,955	459,221	350,264
Change	-	-15.63%	-81.14%	25.1%	1,105.58%	28.78%	-5.31%	-23.73%
Net income ¹	124,086	98,714	17,045	50,747	291,535	376,921	345,056	262,291
Change	-	-20.45%	-82.73%	197.72%	474.49%	29.29%	-8.45%	-23.99%
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million

Estimates

Projected Income Statement - Quarterly - Astellas Pharma Inc.

Fiscal Period: March	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4	2028 Q1
Net sales ¹	326,143	325,523	340,627	303,870	381,791	380,394	402,180	354,254	374,990	392,148	421,932	414,602	473,124	462,497	517,408	459,294	505,794	524,320	571,206	537,925	640,914	594,087	616,881	546,807	515,928
Change	-	-0.19%	4.64%	-10.79%	25.64%	-0.37%	5.73%	-11.92%	5.85%	4.58%	7.6%	-1.74%	14.12%	-2.25%	11.87%	-11.23%	10.12%	3.66%	8.94%	-5.83%	19.15%	-7.31%	3.84%	-11.36%	-5.65%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	70,087	42	100,925	93,070	-65,027	111,203	142,451	152,025	183,638	99,163	234,394	185,550	195,450	112,350	-
Change	-	-	-	-	-	-	-	-	-	-	-	-99.94%	240,197.62%	-7.78%	-169.87%	271.01%	28.1%	6.72%	20.79%	-46%	136.37%	-20.84%	5.34%	-42.52%	-
EBIT ¹	36,090	54,079	79,202	-13,685	33,147	86,744	61,388	-48,250	45,794	5,222	23,103	-48,601	50,657	43,053	-116,191	63,520	94,647	104,731	134,502	48,803	184,506	156,298	122,700	26,500	116,059
Change	-	49.84%	46.46%	-117.28%	342.21%	161.69%	-29.23%	-178.6%	194.91%	-88.6%	342.42%	-310.37%	204.23%	-15.01%	-369.88%	154.67%	49%	10.65%	28.43%	-63.72%	278.06%	-15.29%	-21.5%	-78.4%	337.96%
Charge d'intérêts	-1,717	-	-1,302	-	-2,396	-	-2,803	-	-2,720	-	-2,830	-	-4,495	-	-4,227	-	-5,898	-	-2,446	-	-3,121	-	-	-	-
Earnings before Tax (EBT) ¹	35,830	53,255	78,317	-10,516	31,679	88,801	59,758	-47,877	46,850	5,328	21,452	-48,661	50,495	38,547	-118,359	60,554	90,416	104,190	133,957	48,024	186,514	151,100	119,400	30,986	113,559
Change	-	48.63%	47.06%	-113.43%	401.25%	180.32%	-32.71%	-180.12%	197.85%	-88.63%	302.63%	-326.84%	203.77%	-23.66%	-407.05%	151.16%	49.31%	15.23%	28.57%	-64.15%	288.38%	-18.99%	-20.98%	-74.05%	266.48%
Net income ¹	30,687	40,922	60,886	-8,409	24,812	71,622	48,405	-46,125	33,129	-1,459	18,653	-33,278	37,603	35,908	-97,660	74,896	68,422	79,213	100,379	43,521	141,828	114,248	106,964	35,731	91,565
Change	-	33.35%	48.79%	-113.81%	395.06%	188.66%	-32.42%	-195.29%	171.82%	-104.4%	1,378.48%	-278.41%	213%	-4.51%	-371.97%	176.69%	-8.64%	15.77%	26.72%	-56.64%	225.88%	-19.45%	-6.38%	-66.6%	156.26%
Announcement Date	30/07/21	29/10/21	02/02/22	27/04/22	01/08/22	31/10/22	06/02/23	27/04/23	01/08/23	01/11/23	05/02/24	25/04/24	01/08/24	30/10/24	04/02/25	25/04/25	30/07/25	30/10/25	04/02/26	27/04/26	05/08/26	-	-	-	-

¹JPY in Million

Estimates

Projected Income Statement - Halfyear - Astellas Pharma Inc.

Fiscal Period: March	2023 S1	2024 S1	2025 S1	2026 S1	2027 S1	2028 S1
Net sales ¹	762,185	767,138	935,621	1,030,114	1,242,494	1,169,589
Change	-	0.65%	21.96%	10.1%	20.62%	-5.87%
EBITDA	-	-	-	-	-	-
Change	-	-	-	-	-	-
EBIT ¹	119,891	51,016	93,710	199,378	321,440	302,659
Change	-	-57.45%	83.69%	112.76%	61.22%	-5.84%
Charge d'intérêts	-3,904	-4,989	-9,543	-8,591	-	-
Earnings before Tax (EBT) ¹	120,480	52,178	89,042	194,606	318,940	297,659
Change	-	-56.69%	70.65%	118.56%	63.89%	-6.67%
Net income ¹	96,434	31,670	73,511	147,635	248,454	231,876
Change	-	-67.16%	132.12%	100.83%	68.29%	-6.67%
Announcement Date	31/10/22	01/11/23	30/10/24	30/10/25	-	-

¹JPY in Million

Estimates

Forecast Balance Sheet: Astellas Pharma Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Net Debt ¹	-315,986	-376,840	-335,687	643,054	284,347	-59,299	-480,654	-855,942
Change	-	-19.26%	10.92%	291.56%	-55.78%	-120.85%	-710.56%	-78.08%
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million

Estimates

Cash Flow Forecast: Astellas Pharma Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
CAPEX ¹	30,739	36,441	38,056	37,003	57,723	63,333	60,000	63,333
Change	-	18.55%	4.43%	-2.77%	56%	9.72%	-5.26%	5.56%
Free Cash Flow (FCF) ¹	226,705	291,326	-673,327	157,509	493,466	462,868	549,672	516,238
Change	-	28.5%	-331.12%	123.39%	213.29%	-6.2%	18.75%	-6.08%
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million

Estimates

Forecast Financial Ratios: Astellas Pharma Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Profitability
EBITDA Margin (%)	18.16%	15.72%	11.43%	12.56%	26.98%	32.02%	32.04%	30.59%
EBIT Margin (%)	12.01%	8.76%	1.59%	2.15%	17.89%	21.46%	21.55%	18.79%
EBT Margin (%)	12.1%	8.72%	1.56%	1.63%	17.6%	20.45%	20.78%	17.78%
Net margin (%)	9.57%	6.5%	1.06%	2.65%	13.63%	15.89%	15.62%	13.31%
FCF margin (%)	17.49%	19.18%	-41.99%	8.24%	23.07%	19.52%	24.88%	26.2%
FCF / Net Income (%)	182.7%	295.12%	-3,950.29%	310.38%	169.26%	122.8%	159.3%	196.82%
Profitability
ROA	6.81%	5.53%	3.28%	0.9%	8.44%	13.23%	11.74%	9.22%
ROE	8.7%	6.7%	1.1%	3.3%	17.45%	21.39%	17.67%	13.12%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	2.68x	0.49x	-	-	-
Debt / Free cash flow	-	-	-	4.08x	0.58x	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	2.37%	2.4%	2.37%	1.93%	2.7%	2.67%	2.72%	3.21%
CAPEX / EBITDA (%)	13.06%	15.26%	20.76%	15.41%	10%	8.34%	8.48%	10.51%
CAPEX / FCF (%)	13.56%	12.51%	-5.65%	23.49%	11.7%	13.68%	10.92%	12.27%
Items per share
Cash flow per share ¹	110.2	112.3	97.52	139.6	311.7	329.7	320.7	302.6
Change	-	1.98%	-13.19%	43.13%	123.32%	5.77%	-2.74%	-5.65%
Dividend per Share ¹	50	60	70	74	78	80.15	83.08	85.31
Change	-	20%	16.67%	5.71%	5.41%	2.76%	3.65%	2.69%
Book Value Per Share ¹	799.3	839.3	890.1	845.2	1,021	1,168	1,286	1,356
Change	-	5%	6.05%	-5.04%	20.79%	14.45%	10.04%	5.46%
EPS ¹	67.08	54.24	9.51	28.35	162.8	219	202.4	155.9
Change	-	-19.14%	-82.47%	198.11%	474.14%	34.57%	-7.59%	-22.97%
Nbr of stocks (in thousands)	1,841,831	1,795,756	1,792,986	1,790,107	1,791,411	1,793,014	1,793,014	1,793,014
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-